Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide

被引：32

作者：

Hamaguchi, T ^{[1
]}

Hirose, T ^{[1
]}

Asakawa, H ^{[1
]}

Itoh, Y ^{[1
]}

Kamado, K ^{[1
]}

Tokunaga, K ^{[1
]}

Tomita, K ^{[1
]}

Masuda, H ^{[1
]}

Watanabe, N ^{[1
]}

Namba, M ^{[1
]}

机构：

[1] Hyogo Med Univ, Dept Internal Med, Div Diabet & Metab, Nishinomiya, Hyogo 6638501, Japan

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2004年 / 66卷

关键词：

third-generation sulfonylurea; extrapancreatic effects; insulin resistance; metabolic syndrome;

D O I：

10.1016/j.diabres.2003.12.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multicentric study was conducted to evaluate the efficacy of glimepiride in the oral hypoglycemic agents therapy of type 2 diabetic patients treated with glibenclamide so far, and to claim an adequate use of this new generation sulfonylurea. In 66 diabetic outpatients, glibenclamide was switched to glimepiride. After 6 months' therapy, a significant reduction in fasting plasma IRI was observed in relatively hyperinsulinemic patients. In addition, weight reduction was achieved in patients with insulin resistance during this study. These findings suggest that glimepiride improves insulin resistance in hyperinsulinemic patients treated with glibenclamide. Also, glimepiride is favored especially for overweight, insulin-resistant patients inadequately controlled by glibenclamide. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：S129 / S132

页数：4

共 50 条

[21] Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus
Ose, H
Fukui, M
Kitagawa, Y
Hirata, C
Ichio, N
Kadono, M
Mogami, SI
Onishi, M
Ichida, Y
Nakajima, T
Hasegawa, G
Yoshikawa, T
Nakamura, N
ENDOCRINE JOURNAL, 2005, 52 (05) : 563 - 569
[22] COMPARISON OF MIGLITOL AND GLIBENCLAMIDE IN DIET-TREATED TYPE-2 DIABETIC-PATIENTS
PAGANO, G
MARENA, S
CORGIATMANSIN, L
CRAVERO, F
GIORDA, C
BOZZA, M
ROSSI, CM
DIABETES & METABOLISM, 1995, 21 (03) : 162 - 167
[23] Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients
Aghamohammadzadeh, Naser
Tabrizi, Ali
Niafar, Mitra
Najafipor, Farzad
CASPIAN JOURNAL OF INTERNAL MEDICINE, 2010, 1 (01) : 9 - 11
[24] Exenatide or Glimepiride on Insulin Resistance in Type 2 Diabetic Patients
Derosa, Giuseppe
Putignano, Pietro
Bossi, Antonio C.
Bianchi, Lucio
Querci, Fabrizio
Franzetti, Ivano G.
Guazzini, Barbara
Testori, Giampaolo
Fogari, Elena
Maffioli, Pamela
DIABETES, 2011, 60 : A294 - A294
[25] Predictive factors of response to glimepiride in type 2 diabetic patients
Charpentier, G
Fleury-Lerendu, F
Vaur, L
Altman, JJ
Halimi, S
Derobert, E
Grimaldi, A
DIABETOLOGIA, 2000, 43 : A184 - A184
[26] Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone
Shimizu, H
Monden, T
Nagai, T
Shoda, Y
Sato, T
Yamada, M
Mori, M
DIABETIC MEDICINE, 2005, 22 (02) : 225 - 226
[27] A Comparative Study of Repaglinide & Glibenclamide in Type 2 Diabetic Patients
Shah, Zahid Hussain
Saleem, Khurram
Mahboob, Fatima
Jibran, Rushd
PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2011, 5 (03): : 476 - 479
[28] The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes
Emini-Sadiku, Merita
Car, Nikica
Begolli, Luljeta
Blaslov, Kristina
Haliti, Edmond
Bahtiri, Elton
ENDOCRINE JOURNAL, 2019, 66 (10) : 915 - 921
[29] Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients
Wascher, TC
Boes, U
CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 2005, 25 (01) : 40 - 46
[30] Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients
Kiayias, JA
Vlachou, ED
Theodosopoulou, E
Lakka-Papadodima, E
DIABETES CARE, 2002, 25 (07) : 1251 - 1252

← 1 2 3 4 5 →